Study of the Safety and Effectiveness of Immune Globulin Intravenous (IGIV) for the Treatment of Mild to Moderate Alzheimer Disease

Grants and Contracts Details


• To determine whether IGIV, 10% treatment either at a dose of 400 mglkg body weight (BW)/2 weeks or 200 mg/ kg BW/2 weeks for 9 months results in a significantly slower rate of decline of dementia symptoms in subjects with mild-to-moderate AD as compared to placebo, as measured by ADAS-Cog and the ADCS-CGIC.)
Effective start/end date11/15/086/30/13


  • University of California San Diego Health: $426,015.00


Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.